There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Clearside Biomedical (CLSD – Research Report) and Krystal Biotech (KRYS – Research Report) with bullish sentiments.
Clearside Biomedical (CLSD)
Wedbush analyst Liana Moussatos reiterated a Buy rating on Clearside Biomedical today and set a price target of $6.00. The company’s shares closed last Monday at $2.96.
According to TipRanks.com, Moussatos is a 4-star analyst with an average return of 11.2% and a 47.3% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Eiger Biopharmaceuticals, and BioMarin Pharmaceutical.
Currently, the analyst consensus on Clearside Biomedical is a Moderate Buy with an average price target of $7.00.
Krystal Biotech (KRYS)
William Blair analyst Raju Prasad maintained a Buy rating on Krystal Biotech today. The company’s shares closed last Monday at $80.12, close to its 52-week high of $87.29.
According to TipRanks.com, Prasad is a 4-star analyst with an average return of 14.9% and a 53.0% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Alexion Pharmaceuticals, and Rocket Pharmaceuticals.
Krystal Biotech has an analyst consensus of Strong Buy, with a price target consensus of $108.33, representing a 33.7% upside. In a report issued on April 19, H.C. Wainwright also maintained a Buy rating on the stock with a $103.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.